Search PubMed⌕ Search

Biomedical subjects

L Denis

Publications and source records attributed to L Denis.

At least 163 records · Page 9Linked to original sources
PubMed1983

An EORTC phase II study of vindesine in advanced prostate cancer.

In a phase II study of vindesine in patients with bi-dimensionally measurable primary or metastatic prostate cancer, 27 patients (given 3 mg/m2 weekly for at least 4 treatment cycles) were evaluable for response 6 weeks from the start of treatment. Dose escalation to 4 mg/m2 weekly was attempted. Five patients (19%) achieved a partial remission of short duration, 11 patients (41%) showed no change and 11 patients (41%) showed progression. Thirty-one patients were evaluable for toxicity. Neurotoxicity occurred in 58% (severe in 23%) and was apparently cumulative dose-dependent, although there was variable individual sensitivity. Haematological toxicity was evidenced by lack of dose escalation in 32% of patients, dose delay in 71% and some degree of anaemia in 48%. Alopecia occurred in 55%. Other toxicities were few and minor. Vindesine shows marginal activity in prostatic cancer but at this dose schedule causes appreciable toxicity.

Aged↗
PubMed1983

Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.

A randomized clinical trial was performed on 308 patients with stage T1 carcinoma of the bladder to compare the efficacy of transurethral resection alone or followed by bladder instillations of thiotepa or VM-26 (teniposide) for 1 year. With the recurrence rate as the primary end point of interest the data from this trial were used to assess the prognostic importance of the following factors at entry into the study: number of tumors, prior recurrence rate, tumor size, grade, age, treatment group assigned and, finally, the interval between transurethral resection at entry into the study and the start of intravesical treatment. Using multivariate statistical techniques we found that the number of tumors at presentation was the most important prognostic factor followed by, in order of importance, the recurrence rate at entry and the size of the largest tumor. Of particular note was the discovery that patients with less than 1 recurrence per year at entry had a prognosis similar to patients with primary tumors, while those with a higher recurrence rate did uniformly poorly. These results show that patients with stage T1 carcinoma of the bladder form a heterogeneous group and that more aggressive therapy should be considered for patients with a poor prognosis.

Humans↗
PubMed1983

The practice and pitfalls of ultrasonography in the lower urinary tract.

Real time ultrasound technology is basically performed by three different techniques: transabdominal sector scan; transrectal radial scan, and transurethral radial scan. This review, based on 7 years of experience on more than 2,500 patients, compares the usefulness and limitations of these techniques in the diagnosis of lower urinary tract pathology. Transabdominal ultrasound is used for general evaluation of the lower urinary tract and the determination of residual urine. Transrectal ultrasound determines prostatic mass, diagnoses early prostatic cancer and evaluates exact staging of prostatic cancer and pathology of the seminal vesicles. Transurethral ultrasound is the best technique for preoperative staging of bladder cancer.

Adenoma↗
PubMed1983

[Prostate hypertrophy. Surgical experience in Belgium. Multi-center study of 1,140 patients of 80 years and older].

An inquiry organized by the Belgian Society of Surgery brought data on the mortality and morbidity of surgery on patients of 80 years and older for benign prostatic hypertrophy in a total number of 1,140 operations. Consensus exist to see this surgery as planned surgery. The mortality was 73 (6.3%) without statistical difference between endoscopic and open surgery. The morbidity of 824 patients was 165. This last figure relates to the big series in the literature. The mortality is in direct relation to the age of the patients. Evaluation of cardio-pulmonary risk (70.8% of the mortality), operation on indication at earlier diagnosis and prospective studies on the risk of operation in this population group are indicated.

Aged↗
PubMed1983

Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study.

Thirty-seven patients with measurable deposits or primary lesions arising from transitional cell carcinoma of the bladder were treated with 1 mg/m2/week of vincristine. One complete response lasting 7 months was seen among the 23 patients with metastatic disease. Two partial responses were seen among the 14 patients with persistent primary tumor. Vincristine is not recommended for further evaluation as a single agent in transitional cell carcinoma of the bladder.

Aged↗
PubMed1983

[Surgery in the octogenarian (introduction). Results of a national survey].

Presentation of the results of a national, multicentric and retrospective study regarding the surgery of the octogenarian. The series counts 7,407 patients accepted for surgery, and which can be divided into 4,581 women (61.8%) and 2,826 men (38.2%) of an average age of 84.4 years old (extremities 80-101 years old). The global mortality of this population of elderly (whether operated on or not) amounts to 16.7%. The postoperative mortality of the 4,177 operated patients is 18.2% with different rates according to the surgical disciplines: 34.7% for surgery of the colon, 23.2% for bone surgery, 22.4% for vascular surgery, 15.3% for biliary surgery, 8.7% for urologic surgery and 5.6% for cardiac surgery.

Age Factors↗
PubMed1982

Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.

The Urological Group of the European Organization for Research on Treatment of Cancer (EORTC) has performed a randomized clinical trial designed to compare the disease-free interval, the recurrence rate and the number of patients with increase in tumor stage after transurethral resection (TUR) only or TUR followed by prophylactic bladder instillation of thiotepa or VM26 (an epipodophyllotoxin derivative). Drug instillation was initiated 1 month after TUR and subsequently administered weekly for 4 weeks and then monthly for 1 year. 370 patients from 20 participating institutions in six different countries were admitted to this protocol. 308 eligible patients with follow-up were analyzed. There was no difference among the groups regarding the time of first recurrence (disease-free interval) but thiotepa significantly reduced the recurrence rate as compared to the control group or VM26. When adjusting for primary or recurrent patients stratification, the results remained the same.

Carcinoma, Transitional Cell↗
PubMed1980

Diagnostic contribution of bladder washing and multiple biopsies in bladder cancers.

The superior diagnostic contribution of bladder washing as compared to routine urinary cytology was demonstrated in a prospective study. Random mucosal biopsies of normal-looking mucosa taken at the time of treatment or of the first control cystoscopy revealed the presence of multiple cancerous or precancerous lesions in a variety of patients. The heterogeneity of bladder cancer had to be recognized for adequate follow-up and treatment.

Biopsy↗